Sources inform ''Globes'' that Cybele Holdings Ltd. has invested several million dollars in umbilical cord blood stem cell company CryoCell Israel Ltd. This is Cybele's first investment in a private biomed company, and it may be the first sign of a new policy.
"We will make more investments in private biomed companies in 2011, just as we invest in other sectors affiliated with our other banking and investment activities," said Cybele controlling shareholder Shachar Saidon. "Since 2005, we have aided biomed companies, and we have close ties with more than 60% of public companies. We intend to continue to translate our experience in the field into equity investments in private and public companies with breakthrough biomed, pharmaceutical, and medical devices technologies."
Cybele offers a range of support services for public companies. It specializes in IPO consulting, including preparing companies for offerings and working with underwriters. The company also sells blocs of shares in off-floor transactions for parties at interest seeking to reduce or increase their stakes.
Cybele partner Yael Schnitzer added, "We will invest in companies at stages where Cybele can create value. This will be expressed through the involvement of our team in building a strategy for the company, and our experience in raising capital needed to meet the targets we set."
Cybele's investment can support companies that are a few years away from commercialization, but which do not want to go public, do not want venture capital, or which are not suited for it.
Published by Globes [online], Israel business news - www.globes-online.com - on February 7, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011